Overview from the 2026 International Stroke Conference - Part 2
Release Date: 03/05/2026
History of Letters to the Editor
Neurology Minute
As we celebrate the 75th anniversary of Neurology®, Drs. Jeff Ratliff, Steven Galetta, and Robert Griggs discuss the history and evolution of the Letters to the Editor section. Join the conversation by visiting the .
info_outline
Landmark Clinical Trials Shaping Patient Care
Neurology Minute
Dr. H.E. Hinson and Dr. Vijay Ramanan discuss the upcoming Clinical Trials Plenary Session at the AAN Annual Meeting and the landmark studies shaping neurological care. For more information about this event, .
info_outline
TRPM8 Antagonism with Elismetrep: A Novel Approach for Treating Migraine - Part 1
Neurology Minute
In part one of this series, Dr. Tesha Monteith and Dr. Brett Lauring discuss the potential role TRPM8 antagonist may play in the management of migraine. Read more about this abstract on the .
info_outline
FDA Revises Trial Requirements for Drug and Medical Product Approval - Part 2
Neurology Minute
In part two of this series, Dr. Justin Abbatemarco and Lizzy Lawrence discuss recent FDA guidance, focusing on broader agency changes and how this messaging differs from the FDA’s traditional communication around regulatory decision-making. Show citation:
info_outline
April 2026 President Spotlight: Supporting Neurology in Every Practice Setting
Neurology Minute
In the March episode of the President's Spotlight, Dr. Jason Crowell and Dr. Natalia Rost discuss some of the most pressing challenges facing academic neurology while supporting neurologists in all practice settings. Stay informed by watching the video.
info_outline
Antiseizure Medication Dosing Strategy During Pregnancy and Early Postpartum in Women With Epilepsy in MONEAD
Neurology Minute
Dr. Derek Stitt and Dr. Page B. Pennell discuss antiseizure medication management during pregnancy and postpartum, based on the MONEAD study. Show citation: Pennell PB, Li D, Kerr WT, et al. Antiseizure Medication Dosing Strategy During Pregnancy and Early Postpartum in Women With Epilepsy in MONEAD. Neurology. 2026;106(2):e214483. doi:
info_outline
FDA Revises Trial Requirements for Drug and Medical Product Approval - Part 1
Neurology Minute
In part one of this series, Dr. Justin Abbatemarco and Lizzy Lawrence discuss the FDA’s shift toward single-trial drug approvals. Show citation:
info_outline
Real-World Implementation of an AI Clinical Assistant in Neurology
Neurology Minute
Dr. Halley Alexander and Dr. Mikael Guzman Karlsson discuss the development and evaluation of an AI-enabled clinical assistant designed to support time-sensitive decision-making in neurology. View the related abstract:
info_outline
A Roadmap to Neurological Health Equity - Part 2
Neurology Minute
In part two of this series, Dr. Tesha Monteith and Dr. Nimish A. Mohile discuss the motivation behind the development of this roadmap to neurological health equity. Show citation: Patel PB, Hamilton RH, Budhu JA, et al. A Roadmap to Neurologic Health Equity: An AAN Position Statement. Neurology. 2026;106(5):e214687. doi:
info_outline
A Roadmap to Neurological Health Equity - Part 1
Neurology Minute
In the first part of this series, Dr. Tesha Monteith and Dr. Nimish A. Mohile discuss what the roadmap is and how it is intended to benefit practicing neurologists. Show citation: Patel PB, Hamilton RH, Budhu JA, et al. A Roadmap to Neurologic Health Equity: An AAN Position Statement. Neurology. 2026;106(5):e214687. doi:
info_outlineIn part two of the series, Dr. Andy Southerland and Dr. Seemant Chaturvedi break down key takeaways from the OCEANIC‑STROKE trial.
Show citation:
Read more about the OCEANIC-STROKE trial.
Show transcript:
Dr. Andy Southerland:
Hello everyone. This is Andy Southerland from the University of Virginia. For today's Neurology Minute, I've just been speaking with my colleague, Seemant Chaturvedi from the University of Maryland, about exciting trials presented at this year's 2026 International Stroke Conference from the American Heart Association, American Stroke Association. And the one we want to discuss for today's Neurology Minute in brief was the OCEANIC-STROKE trial. This was a very large international trial looking at the use of a novel antithrombotic agent, a Factor XI inhibitor, compared to placebo as an adjunct to our traditional antiplatelet therapies for secondary stroke prevention. And it was received with quite a bit of excitement. So Seemant, tell us in brief, what did we learn from OCEANIC-STROKE?
Dr. Seemant Chaturvedi:
One new class of agents, which is being tested are the Factor XIa inhibitors. And this has a unique mechanism of action, and it's believed that it can reduce thrombotic events without causing an increase in bleeding, which would be truly a major breakthrough. And so in OCEANIC-STROKE, over 12,000 patients were enrolled with either stroke or high-risk TIA within 72 hours of the last event. And the trial found that patients who had fairly mild strokes with a median NIH score of two, that when you add the asundexian 50 milligrams per day on top of either dual antiplatelet or single antiplatelet therapy, that there was an improved outcome and reduction in stroke with asundexian. There was a 2.2% absolute reduction in ischemic stroke, 26% in relative terms. Stroke, MI, and vascular death was also reduced with asundexian, as was disabling stroke. An exciting finding was that major bleeding was not increased with asundexian.
And so this confirmed the preclinical hypothesis. And so I think this was a significant result in terms of reducing recurrent ischemic stroke without increasing bleeding. And so I think we eagerly await the full publication, and I think it could be applicable to many of the patients that we see in our clinical practice.
Dr. Andy Southerland:
So asundexian, folks, you'll hear more about this as the drug hopefully comes on the market and we see the full primary publication of this OCEANIC-STROKE trial, but exciting nonetheless to have a possible new treatment to help us reduce the risk of recurrent stroke for our patients. So Seemant, thanks so much again for joining us for today's Neurology Minute. And I encourage all of our listeners, as always, to listen to the full podcast interview ain The Neurology Podcast. Seemant, thanks for joining us.
Dr. Seemant Chaturvedi:
My pleasure.